Бедаквилин снижает смертность среди пациентов с устойчивым ТБ

Васьвась

Bedaquiline-based regimens are associated with large reductions in mortality in people with drug-resistant tuberculosis, according to research conducted in South Africa and published in The Lancet Respiratory Medicine.

Compared to standard regimens, use of bedaquiline reduced the risk of all cause mortality by 75% in people with extensively drug-resistant tuberculosis (XDR-TB) and by 65% for people with rifampicin-resistant or multidrug-resistant tuberculosis (MDR-TB)